Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) activating mutations have recently shown great promise as potential therapeutic targets in glioma [27,28,29]. Here, PIK3CA is linked to central nervous system cancer.